Interleukin-15 liver gene transfer increases the number and function of IKDCs and NK cells

Gene Therapy

Volumn 15, Issue 7, 2008, Pages 473-483

  Arina, A ^a   Murillo, O ^a   Dubrot, J ^a   Azpilikueta, A ^a   Gabari, I ^a   Perez Gracia, J L ^a,b   Alfaro, C ^a   Berasain, C ^a   Prieto, J ^a,b   Ferrini, S ^c   Hervas Stubbs, S ^a   Melero, I ^a,b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD137 LIGAND; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 15; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL COUNT; CELL FUNCTION; CELL PROLIFERATION; CELL SUBPOPULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOLYSIS; DENDRITIC CELL; GENE CASSETTE; GENE EXPRESSION; GENE TRANSFER; HYDRODYNAMICS BASED TRANSFECTION; INTERFERON PRODUCING KILLER DENDRITIC CELL; LEUKOCYTE; LIVER; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN;

ADOPTIVE TRANSFER; ANIMALS; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; FLOW CYTOMETRY; GENE THERAPY; GENES, RAG-1; HUMANS; INJECTIONS, INTRAVENOUS; INTERLEUKIN-15; KILLER CELLS; KILLER CELLS, NATURAL; LIVER; LYMPHOCYTE COUNT; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPLEEN; TRANSFECTION;

MUS;

EID: 40949132423     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2008.4     Document Type: Article

References (44)

1. Chan CW, Crafton E, Fan HN, Flook J, Yoshimura K, Skarica M et al. Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity. Nat Med 2006; 12: 207-213.
2. Taieb J, Chaput N, Menard C, Apetoh L, Ullrich E, Bonmort M et al. A novel dendritic cell subset involved in tumor inummosurveillance. Nat Med 2006; 12: 214-219.
3. Pillarisetty VG, Katz SC, Bleier JI, Shah AB, Dematteo RP. Natural killer dendritic cells have both antigen presenting and lytic function and in response to CpG produce IFN-gamma via autocrine IL-12. J Immunol 2005; 174: 2612-2618.
4. Plitas G, Chaudhry UI, Kingham TP, Raab JR, DeMatteo RP. NK dendritic cells are innate immune responders to Listeria monocytogenes infection. J Immunol 2007; 178: 4411-4416.
5. + lymphoid progenitors. Blood 2007; 22: 22.
6. Ullrich E, Bonmort M, Mignot G, Chaput N, Thieb J, Menard C et al. Therapy-induced tumor immunosurveillance involves IFN-producing killer dendritic cells. Cancer Res 2007; 67: 851-853.
7. Spits H, Lanier LL. Natural killer or dendritic: What's in a name? Immunity 2007; 26: 11-16.
8. + interferon-producing killer dendritic cells are activated natural killer cells. J Exp Med 2007; 204: 2569-2578.
9. + cells identify them as a subset of NK cells. J Exp Med 2007; 204: 2561-2568.
10. Caminschi I, Ahmet F, Heger K, Brady J, Nutt SL,Vremec D et al. Putative IKDCs are functionally and developmentally similar to natural killer cells, but not to dendritic cells. J Exp Med 2007; 204 2579-2590.
11. Budagian V, Bulanova E, Paus R, Bulfone-Paus S. IL-15/IL-15 receptor biology: A guided tour through an expanding universe. Cytokine Growth Factor Rev 2006; 17: 259-280.
12. Becknell B, Caligiuri MA. Interleukin-2, interleukin-15, and their roles in human natural killer cells. Adv Immunol 2005; 86: 209-239.
13. Kennedy MK, Glaccum M, Brown SN, Butz EA, Viney JL, Embers M et al Reversible defects in natural killer and memory CD8T cell lineages in interleukin 15-deficient mice. J Exp Med 2000; 191: 771-780.
14. + T cells. J Exp Med 2001; 193: 219-231.
15. Lodolce JP, Boone DL, Chai S, Swain RE, Dassopoulos T, Trettin S et al. IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity 1998; 9: 669-676.
16. Koka R, Burkett PR, Chien M, Chai S, Chan F, Lodolce JP et al. Interleukin (IL)-15R[alpha]-deficient natural killer cells survive in normal but not IL-15R[alpha]-deficient mice. J Exp Med 2003; 197: 977-984.
17. Carson WE, Giri JG, Lindemann MJ, Linett ML, Ahdieh M, Paxton R et al Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med 1994; 180: 1395-1403.
18. Dubois S, Mariner J, Waldmann TA, Tagaya Y. IL-15Ralpha recycles and presents IL-15 in trans to neighboring cells. Immunity 2002; 17 537-547.
19. Waldmann TA. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol 2006; 6: 595-601.
20. Kobayashi H, Dubois S, Sato N, Sabzevari H, Sakai Y, Waldmann TA et al. Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor inummosurveillance, Blood 2005; 105: 721-727.
21. Niidome T, Huang L. Gene therapy progress and prospects: Nonviral vectors. Gene Ther 2002; 9: 1647-1652.
22. He Y, Pimenov AA, Nayak JV, Plowey J, Falo Jr LD, Huang L. Intravenous injection of naked DNA encoding secreted flt3 ligand dramatically increases the number of dendritic cells and natural killer cells in vivo. Hum Gene Ther 2000; 11: 547-554.
23. Ortaldo JR, Winkler-Pickett RT, Bere Jr EW, Watanabe M, Murphy WJ, Wiltrout RH. In vivo hydrodynamic delivery of cDNA encoding IL-2: rapid, sustained redistribution, activation of mouse NK cells, and therapeutic potential in the absence of NKT cells. J Immunol 2005; 175: 693-699.
24. Hazama S, Noma T, Wang F, Iizuka N, Ogura Y, Yoshimura K et al. Tumour cells engineered to secrete interleukin-15 augment anti-tumour immune responses in vivo. Br J Cancer 1999; 80: 1420-1426.
25. Di Carlo E, Comes A, Basso S, De Ambrosis A, Meazza R, Musiani P et al. The combined action of IL-15 and IL-12 gene transfer can induce tumor cell rejection without T and NK cell involvement. J Immunol 2000; 165: 3111-3118.
26. Kishida T, Asada H Itokawa Y, Cui FD, Shin-Ya M, Gojo S et al. Interleukin (IL)-21 and IL-15 genetic transfer synergistically augments therapeutic antitumor immunity and promotes regression of metastatic lymphoma. Mol Ther 2003; 8: 552-558.
27. Croce M, Meazza R, Orengo AM, Radic L, De Giovanni B, Gambini C et al Sequential immumogene therapy with interleukin-12- and interleukin-15-engineered neuroblastoma cells cures metastatic disease in syngeneic mice. Clin Cancer Res 2005; 11: 735-742.
28. Meazza R, Lollini PL, Nanni P, De Giovanni C, Gaggero A, Comes A et al. Gene transfer of a secretable form of IL-15 in murine adenocarcinoma cells: Effects on tumorigenicity, metastatic potential and immune response. Int J Cancer 2000; 87: 574-581.
29. + T lymphocytes and NK cells. Mol Ther 2005; 12: 950-959.
30. Stoklasek TA, Schluns KS, Lefrancois L. Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo. J Immunol 2006; 177: 6072-6080.
31. Suzuki A, McCall S, Choi SS, Sicklick JK, Huang J, Qi Y et al. Interleukin-15 increases hepatic regenerative activity. J Hepatol 2006; 45: 410-418.
32. Mehal WZ, Azzaroli F, Crispe IN. Immunology of the healthy liver: Old questions and new insights. Gastroenterology 2001; 120: 250-260.
33. Chen L, Calomeni E, Wen J, Ozato Y, Shen R, Gao JX. Natural killer dendritic cells are an intermediate of developing dendritic cells. J Leukoc Biol 2007; 1: 1.
34. Melero I, Johnston JV, Shufford WW, Mittler R$, Chen L. NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. Cell Immunol 1998; 190:167-172.
35. Qin L, Ding Y, Pahud DR, Chang E, Impetiale MJ, Bromberg JS. Promoter attenuation in gene therapy: Interferon-gamma and tumor necrosis factor-alpha inhibit transgene expression. Hum Gene Ther 1997; 8: 2019-2029.
36. Wang L, Hernandez-Alcoceba R, Shankar V, Zabala M, Kochanek S, Sangro B et al. Prolonged and inducible transgene expression in the liver using gutless adenovirus: A potential therapy for liver cancer. Gastroenterology 2004; 126: 278-289.
37. Rubinstein MP, Kovar M, Purtan JF, Cho JH, Boyam O, Surh CD et al. Converting IL-15 to a superagonist by binding to soluble IL-15R(alpha). Proc Natl Acad Sci USA 2006; 103: 9166-9171.
38. Sato N, Patel HJ, Waldmann TA, Tagaya Y. The IL-15/IL-15Ralpha on cell surfaces enables sustained IL-15 activity and contributes to the long survival of CD8 memory T cells. Proc Natl Acad Sci USA 2007; 104: 588-593.
39. Chaudhry UI, Plitas G, Burt BM, Kingham TP, Raab JR, DeMatteo RP. NK dendritic cells expanded in IL-15 exhibit antitumor responses in vivo. J Immunol 2007; 179: 4654-4660.
40. Waldmann TA. Effective cancer therapy through immunomodulation. Annu Rev Med 2006; 57: 65-81.
41. + T cells. Proc Natl Acad Sci USA 2004; 101: 1969-1974.
42. Waldmann TA. The biology, of interleukin-2 and interleukin-15: implications for cancer therapy, and vaccine design. Nat Rev Immunol 2006; 6: 595-601.
43. Maraskovsky E, Brasel K, Teepe M, Roux ER, Lyman SD, Shortman K et al Dramatic increase in the numbers of ftmctionally mature dendritic cells in 170 ligand-treated mice: Multiple dendritic cell subpopulations identified. J Exp Med 1996; 184: 1953-1962.
44. Shortman K, Villadangos JA. Is it a DC, is it an NK? No, it's an IKDC. Nat Med 2006; 12: 167-168.